SPHK2 and glioblastoma: Recent studies have shown SK2 localization to be regulated by the cytoplasmic protein cytoplasmic dynein 1 intermediate chain 1 (DYNC1I1), which is highly downregulated in GBM, with low DYNC1I1 associated with poor patient prognosis [245].